News

NCCN, a not-for-profit alliance of 26 of the world’s leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency

In February 2015, the company licensed exclusive, worldwide rights in its adenosine receptor antagonist programme for use in all therapeutic applications to Corvus, a U.S.-based biotechnology company. At

Under the terms of the agreement, X-Chem is applying its discovery engine, which leverages a high diversity, proprietary DNA-encoded small molecule library to seek the identification of novel

The formal authorizations from regulatory agencies in France, Italy and Czech Republic, and the positive opinions from national ethic committees in these three countries enable the initiation of

The selected candidate, ImmTAC, will address a target relevant in several cancer indications such as synovial sarcoma, bladder and non-small cell lung (NSCL) cancers. Immunocore will carry out

The drug had no serious adverse events, bleeding or injection site reactions, the company said. The 59-patient trail has revealed that patients who were given 30 mg and

EMB-001 is a patented combination product comprising metyrapone and oxazepam drugs, which have been approved by the US Food and Drug Administration. It targets the stress response system

The acquisition was funded through cash on hand. The assets were acquired from a Dutch subsidiary of Merck by ANI Pharmaceuticals C.V., a Netherlands based wholly owned indirect

The trial is evaluating the use of Pexa-Vec to treat HCC patients who have failed locoregional therapies and are eligible for treatment with sorafenib (Nexavar), the only approved